Combined with single-cell sequencing, this approach will help us analyze the heterogeneity of ccRCC cells in response to VEGFR and MEK inhibitor treatments, which will aid in uncovering deeper mechanisms. The gene discussed is MAP2K7; the disease is nonpapillary renal cell carcinoma.